BRAF V600E status and clinical characteristics in solitary and multiple papillary thyroid carcinoma: Experience of 512 cases at a clinical center in China

World Journal of Surgical Oncology

Volumn 10, Issue , 2012, Pages

  Zheng, Xiangqian ^a   Xia, Tingting ^a   Lin, Lin ^a   Gao, Songyuan ^b   Lee, Yigong ^a   Yu, Yang ^a   Wei, Songfeng ^a   Gao, Ming ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b TSINGHUA UNIVERSITY   (China)

Author keywords

BRAF V600E mutation; Multiple ptc; Papillary thyroid carcinoma; Solitary ptc

Indexed keywords

B RAF KINASE; BRAF PROTEIN, HUMAN;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER INVASION; CANCER STAGING; CHILD; CHINA; CLINICAL FEATURE; CONTROLLED STUDY; DISTANT METASTASIS; EVALUATION; FEMALE; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MULTIPLE PAPILLARY THYROID CARCINOMA; MUTATION; PRESCHOOL CHILD; RETROSPECTIVE STUDY; SCHOOL CHILD; SOLITARY PAPILLARY THYROID CARCINOMA; SURVIVAL RATE; THYROID CARCINOMA; FOLLOW UP; GENETICS; MIDDLE AGED; MORTALITY; PAPILLARY CARCINOMA; PROGNOSIS; THYROID TUMOR;

ADOLESCENT; ADULT; AGED; CARCINOMA, PAPILLARY; CHILD; CHILD, PRESCHOOL; CHINA; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; PROGNOSIS; PROTO-ONCOGENE PROTEINS B-RAF; RETROSPECTIVE STUDIES; SURVIVAL RATE; THYROID NEOPLASMS; YOUNG ADULT;

EID: 84861922322     PISSN: None     EISSN: 14777819     Source Type: Journal    
DOI: 10.1186/1477-7819-10-104     Document Type: Article

References (40)

1. Hundahl SA, Fleming ID, Fremgen AM, Menck HR. A national cancer data base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995. Cancer 1998, 83:2638-2648. 10.1002/(SICI)1097-0142(19981215)83:12<2638::AID-CNCR31>3.0.CO;2-1, 9874472.
2. Schlumberger MJ. Papillary and follicular thyroid carcinoma. N Eng J Med 1998, 338:297-306.
3. Davies L, Welch HG. Thyroid cancer survival in the United States: observational data from 1973 to 2005. Arch Otolaryngol Head Neck Surg 2010, 136(5):440-444. 10.1001/archoto.2010.55, 20479371.
4. Leenhardt L, Bernier MO, Boin-Pineau MH. Advances in diagnostic practices affect thyroid cancer incidence in France. Eur J Endocrinol 2004, 150(2):133-139. 10.1530/eje.0.1500133, 14763910.
5. Carcangiu ML, Zampi G, Pupi A, Castagnoli A, Rosai J. Papillary carcinoma of the thyroid. A clinicopathologic study of 241 cases treated at the University of Florence, Italy. Cancer 1985, 55:805-828. 10.1002/1097-0142(19850215)55:4<805::AID-CNCR2820550419>3.0.CO;2-Z, 3967175.
6. Russell WO, Ibanez ML, Clark RL, White EC. Thyroid carcinoma classification, intraglandular dissemination, and clinicopathological study based upon whole organ section of 80 glands. Cancer 1963, 16:1425-1460. 10.1002/1097-0142(196311)16:11<1425::AID-CNCR2820161106>3.0.CO;2-E, 14086580.
7. Udelsman R, Chen H. The current management of thyroid cancer. Adv Surg 1999, 33:1-27.
8. DeLellis RA. Pathology and genetics of thyroid carcinoma. J Surg Oncol 2006, 94:662-669. 10.1002/jso.20700, 17131411.
9. Katoh R, Sasaki J, Kurihara H, Suzuki K, Iida Y, Kawaoi A. Multiple thyroid involvement (intraglandular metastasis) in papillary thyroid carcinoma. A clinicopathologic study of 105 consecutive patients. Cancer 1992, 70:1585-1590. 10.1002/1097-0142(19920915)70:6<1585::AID-CNCR2820700623>3.0.CO;2-Z, 1516009.
10. Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994, 97:418-428. 10.1016/0002-9343(94)90321-2, 7977430.
11. De Matos PS, Ferreira AP, Ward LS. Prevalence of papillary microcarcinoma of the thyroid in Brazilian autopsy and surgic series. Endocr Pathol 2006, 17:165-173. 10.1385/EP:17:2:165, 17159249.
12. Sugg SL, Ezzat S, Rosen IB, Freeman JL, Asa SL. Distinct multiple RET/PTC gene rearrangements in multiple papillary thyroid neoplasia. J Clin Endocrinol Metab 1998, 83:4116-4122. 10.1210/jc.83.11.4116, 9814501.
13. Moniz S, Catarino AL, Marques AR, Cavaco B, Sobrinho L, Leite V. Clonal origin of non-medullary thyroid tumours assessed by non-random X-chromosome inactivation. Eur J Endocrinol 2002, 146:27-33. 10.1530/eje.0.1460027, 11751063.
14. Shattuck TM, Westra WH, Ladenson PW, Arnold A. Independent clonal origins of distinct tumor foci in multiple papillary thyroid carcinoma. N Engl J Med 2005, 352:2406-2412. 10.1056/NEJMoa044190, 15944425.
15. Roti E, Degli Uberti EC, Bondanelli M, Braverman LE. Thyroid papillary microcarcinoma: a descriptive and meta-analysis study. Eur J Endocrinol 2008, 159:659-673. 10.1530/EJE-07-0896, 18713843.
16. Pazaitou-Panayiotou K, Capezzone M, Pacini F. Clinical features and therapeutic implication of papillary thyroid microcarcinoma. Thyroid 2007, 17:1085-1092. 10.1089/thy.2007.0005, 18047430.
17. Hay ID, Grant CS, Van Heerden JA, Goellner JR, Ebersold JR, Bergstralh EJ. Papillary thyroid microcarcinoma: a study of 535 cases observed in a 50-year period. Surgery 1992, 112:1139-1146. discussion 1146-1137.
18. Baudin E, Travagli JP, Ropers J, et al. Microcarcinoma of the thyroid gland: the Gustave-Roussy Institute experience. Cancer 1998, 83:553-559. 10.1002/(SICI)1097-0142(19980801)83:3<553::AID-CNCR25>3.0.CO;2-U, 9690549.
19. Chow SM, Law SC, Chan JK, Au SK, Yau S, Lau WH. Papillary microcarcinoma of the thyroid prognostic significance of lymph node metastasis and multiple. Cancer 2003, 98:31-40. 10.1002/cncr.11442, 12833452.
20. ItoK S, OzakiO M, IwasakiH I. Papillary microcarcinoma of the thyroid. J Endocrinol Invest 1998, 21:445-448.
21. Aherne S, Smyth PC, Flavin RJ. Geographical mapping of a multiple thyroid tumour using genetic alteration analysis & miRNA profiling. Mol Cancer 2008, 7:89. 10.1186/1476-4598-7-89, 2612696, 19055826.
22. Namba H, Nakashima M, Hayashi T, Hayashida N, Maeda S, Rogounovitch TI, et al. Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid carcinoma. J Clin Endocrinol Metab 2003, 88:4393-4397. 10.1210/jc.2003-030305, 12970315.
23. Nikiforova MN, Kimura ET, Gandhi M, Biddinger PW, Knauf JA, Basolo F, et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 2003, 88:5399-5404. 10.1210/jc.2003-030838, 14602780.
24. Xu X, Quiros RM, Gattuso P, Ain KB, Prinz RA. High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines. Cancer Res 2003, 63:4561-4567.
25. Kim KH, Kang DW, Kim SH, Seong IO, Kang DY. Mutations of the BRAF gene in papillary thyroid carcinoma in a Korean population. Yonsei Med J 2004, 45:818-821.
26. Puxeddu E, Moretti S, Elisei R, Romei C, Pascucci R, Martinelli M, et al. BRAF (V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas. J Clin Endocrinol Metab 2004, 89:2414-2420. 10.1210/jc.2003-031425, 15126572.
27. Mazeh H, Samet Y, Hochstein D, Mizrahi I, Ariel I, Eid A, Freund HR. Multiple in well-differentiated thyroid carcinomas calls for total thyroidectomy. Am J Surg 2010, 9:22.
28. Vriens MR, Suh I, Moses W, et al. Clinical features and genetic predisposition to hereditary nonmedullary thyroid cancer. Thyroid 2009, 19:1343-1349. 10.1089/thy.2009.1607, 20001717.
29. Huang BY, Lin JD, Chao TC. Therapeutic outcomes of papillary thyroid cancer patients in different risk groups. Oncology 2011, 80(1-2):123-129.
30. Bozec A, Dassonville O, Chamorey E. Clinical impact of cervical lymph node involvement and central neck dissection in patients with papillary thyroid carcinoma: a retrospective analysis of 368 cases. Eur Arch Otorhinolaryngol 2011, 268(8):1205-1212. 10.1007/s00405-011-1639-2, 21607578.
31. Iida F, Yonekura M, Miyakawa M. Study of intraglandular dissemination of thyroid cancer. Cancer 1969, 24:764-771. 10.1002/1097-0142(196910)24:4<764::AID-CNCR2820240416>3.0.CO;2-S, 5821759.
32. Xiaoqi L, Finkelstein SD, Bing Z, Silverman JF. Molecular analysis of multiple papillary thyroid carcinoma. J Mol Endocrinol 2008, 41:195-203. 10.1677/JME-08-0063, 18628356.
33. Xing M, et al. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev 2007, 28:742-762. 10.1210/er.2007-0007, 17940185.
34. Frasca F, et al. BRAF(V600E) mutation and the biology of papillary thyroid cancer. Endocr Relat Cancer 2008, 15:191-205. 10.1677/ERC-07-0212, 18310287.
35. Lee JH, Lee ES, Kim YS. Clinicopathologic significance of BRAF V600E mutation in papillary carcinomas of the thyroid. Cancer 2007, 110:38-46. 10.1002/cncr.22754, 17520704.
36. Nucera C, Goldfarb M, Hodin R, et al. Role of B-Raf (V600E) in differentiated thyroid cancer and preclinical validation of compounds against B-Raf (V600E). Biochim Biophys Acta 2009, 1795(2):152-161.
37. Kim TY, Kim WB, Rhee YS, et al. The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma. Clin Endocrinol (Oxf) 2006, 65:364-368.
38. Howell GM, Carty SE, Armstrong MJ. Both BRAF V600E mutation and older age (>65 Years)are associated with recurrent papillary thyroid cancer. Ann Surg Oncol 2011, 5:19.
39. Trovisco V, de Vieira Castro I, Soares P, Ma'ximo V, Silva P, Magalhaes J, et al. BRAF mutations are associated with histologic types of papillary thyroid carcinoma. J Pathol 2004, 202:247-251. 10.1002/path.1511, 14743508.
40. Trovisco V, Soares P, Preto A, de Vieira Castro I, Lima J, Castro P, et al. Type and prevalence of BRAF mutations are closely associated with papillary thyroid carcinoma histotype and patients' age but not with tumour aggressiveness. Virchows Arch 2005, 446:589-595. 10.1007/s00428-005-1236-0, 15902486.